The Source Blog
Recent Action in Pharmaceuticals
Mo. Rev. Stat. §§ 376.1350 through 376.1389: Health Care Utilization Review – Missouri
Introduced: Status: Enacted
A utilization review program shall use documented clinical review criteria that are based on sound clinical evidence and are evaluated periodically to assure ongoing efficacy. A health carrier may develop its own clinical review criteria, […]
Download
Cal. Health & Safety Code §§ 127675 through 127686: Prescription Drug Pricing for Purchasers – California
Introduced: Status: Enacted
It is the intent of the Legislature in enacting this chapter to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability to the state […]
Download
Tex. Occ. Code §§ 157.051 through 157.060: Physicians– Authority of Physician to Delegate Certain Medical Acts – Texas
Introduced: Status: Enacted
A physician may delegate to an advanced practice registered nurse or physician assistant, acting under adequate physician supervision, the act of prescribing or ordering a drug or device as authorized through a prescriptive authority agreement.
Download
Or. Rev. Stat. §§ 743B.250 through 743B.258: Health Benefit Plans: Individual and Group — Grievances and Appeals – Oregon
Introduced: Status: Enacted
Provides the process for appeal and external review. Requires an insurer to provide all information relating to benefit design and provider networks. States that an insurer must have an external review program to assess whether […]
Download
Or. Rev. Stat. § 743A.082. Diabetes management for pregnant women: Health Insurance: Reimbursement of Claims – Oregon
Introduced: Status: Enacted
States that a health benefit plan may not require a copayment or impose a coinsurance requirement or deductible on the covered services, medications and supplies that are medically necessary for a woman to manage her […]
Download
Or. Rev. Stat. §§ 743.028 through 743.035: Health and Life Insurance — General Provisions (Forms and Standards) – Oregon
Introduced: Status: Enacted
The Department of Consumer and Business Services, in consultation with the Oregon Health Authority, shall develop by rule a form that providers in this state shall use to request prior authorization for prescription drug benefits.
Download
Or. Rev. Stat. § 678.390. Authority of nurse practitioner and clinical nurse specialist to write prescriptions or dispense drugs; notice; requirements; revocation; rules: Professional Nurses (Prescriptive Authority) – Oregon
Introduced: Status: Enacted
The Oregon State Board of Nursing may authorize a certified nurse practitioner or certified clinical nurse specialist to write prescriptions, including prescriptions for controlled substances listed in schedules II, III, III N, IV and V.
Download
Next | See all Legislation Records
Introduced: Status: Enacted
A utilization review program shall use documented clinical review criteria that are based on sound clinical evidence and are evaluated periodically to assure ongoing efficacy. A health carrier may develop its own clinical review criteria, […]
Download
Cal. Health & Safety Code §§ 127675 through 127686: Prescription Drug Pricing for Purchasers – California
Introduced: Status: Enacted
It is the intent of the Legislature in enacting this chapter to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability to the state […]
Download
Tex. Occ. Code §§ 157.051 through 157.060: Physicians– Authority of Physician to Delegate Certain Medical Acts – Texas
Introduced: Status: Enacted
A physician may delegate to an advanced practice registered nurse or physician assistant, acting under adequate physician supervision, the act of prescribing or ordering a drug or device as authorized through a prescriptive authority agreement.
Download
Or. Rev. Stat. §§ 743B.250 through 743B.258: Health Benefit Plans: Individual and Group — Grievances and Appeals – Oregon
Introduced: Status: Enacted
Provides the process for appeal and external review. Requires an insurer to provide all information relating to benefit design and provider networks. States that an insurer must have an external review program to assess whether […]
Download
Or. Rev. Stat. § 743A.082. Diabetes management for pregnant women: Health Insurance: Reimbursement of Claims – Oregon
Introduced: Status: Enacted
States that a health benefit plan may not require a copayment or impose a coinsurance requirement or deductible on the covered services, medications and supplies that are medically necessary for a woman to manage her […]
Download
Or. Rev. Stat. §§ 743.028 through 743.035: Health and Life Insurance — General Provisions (Forms and Standards) – Oregon
Introduced: Status: Enacted
The Department of Consumer and Business Services, in consultation with the Oregon Health Authority, shall develop by rule a form that providers in this state shall use to request prior authorization for prescription drug benefits.
Download
Or. Rev. Stat. § 678.390. Authority of nurse practitioner and clinical nurse specialist to write prescriptions or dispense drugs; notice; requirements; revocation; rules: Professional Nurses (Prescriptive Authority) – Oregon
Introduced: Status: Enacted
The Oregon State Board of Nursing may authorize a certified nurse practitioner or certified clinical nurse specialist to write prescriptions, including prescriptions for controlled substances listed in schedules II, III, III N, IV and V.
Download
Next | See all Legislation Records
Pharm. Care Mgmt. Ass’n v. Tufte – North Dakota
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act […]
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in […]
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of […]
In re: Flonase Antitrust Litigation – Louisiana, Pennsylvania
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline […]
Mohr-Lercara v. Oxford Health Ins., Inc. – New York
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that […]
In Re UnitedHealth Group PBM Litigation – Minnesota
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay […]
Negron v. Cigna and OptumRx – Connecticut
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription […]
Previous | Next | See all Litigation Records
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act […]
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in […]
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of […]
In re: Flonase Antitrust Litigation – Louisiana, Pennsylvania
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline […]
Mohr-Lercara v. Oxford Health Ins., Inc. – New York
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that […]
In Re UnitedHealth Group PBM Litigation – Minnesota
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay […]
Negron v. Cigna and OptumRx – Connecticut
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription […]
Previous | Next | See all Litigation Records
News & Opinions
Articles & Reports
Health Affairs
October 8, 2025
New England Journal of Medicine October 4, 2025
Milbank Quarterly September 15, 2025
Review of Evolutionary Political Economony September 3, 2025
New England Journal of Medicine October 4, 2025
Milbank Quarterly September 15, 2025
Review of Evolutionary Political Economony September 3, 2025
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered